Colorectal cancer market will remain steady at $7.7 billion by 2023; report

29 August 2014

The market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the USA, France, Germany, Italy, Spain, the UK and Japan, according to new research from Decision Resources Group.

This forecasts that the biosimilar erosion of Roche/Genentech/Chugai's Avastin (bevacizumab) and Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux (cetuximab) will be balanced out by the launch of Eli Lilly's Cyramza (ramucirumab), Taiho Pharmaceutical's Lonsurf (trifluridine and tipiracil hydrochloride), Alchemia's HA-irinotecan and Boehringer Ingelheim's Vargatef (nintedanib), as well as increased uptake of Sanofi/Regeneron's Zaltrap (ziv-aflibercept) and Amgen/Takeda's Vectibix (panitumumab).

Other key findings from the Pharmacor report, titled Colorectal Cancer, are:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >